IBS

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

Wednesday, December 1, 2021 - 12:05pm

The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.

Key Points: 
  • The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
  • The 143-patient Phase 2a trial demonstrated that IMC-1 met its primary endpoint of pain reduction and was statistically better tolerated than placebo.
  • Reaching this enrollment milestone on a timely basis indicates that we are currently on track to report top line results in Q3 of 2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

metaMe Health Receives FDA Clearance for Regulora®, the First FDA-authorized Treatment Specifically for Abdominal Pain Due to Irritable Bowel Syndrome (IBS)

Tuesday, November 30, 2021 - 7:30pm

Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice.

Key Points: 
  • Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice.
  • "The FDA's clearance of Regulora, our first PDT, is a major achievement for the company," said Tim Rudolphi, CEO of metaMe Health.
  • Irritable Bowel Syndrome is a chronic condition of the lower gastrointestinal tract that affects 10-15% of adults in the United States.
  • PDTs are developed under rigorous conditions complete with clinical trials, FDA clearance, and availability only through a physician's prescription.

Ardelyx Launching IBSRELA® Second Quarter of 2022

Tuesday, November 30, 2021 - 12:00pm

This market is ripe for the entry of a novel therapeutic option like IBSRELA, as existing therapies do not adequately address all patient treatment needs.

Key Points: 
  • This market is ripe for the entry of a novel therapeutic option like IBSRELA, as existing therapies do not adequately address all patient treatment needs.
  • We will use the next few months to build commercial inventory and prepare the market for a second-quarter 2022 launch.
  • "The approval of IBSRELA was based on two successful Phase 3 trials involving over 1,200 patients with IBS-C.
  • Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022.

AI gut-imaging software takes on the US with FDA clearance and national hospital partnership

Tuesday, November 23, 2021 - 1:00pm

The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.

Key Points: 
  • The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.
  • Supporting the move into the US healthcare market, the company has also announced a new partnership with AI patient-care software provider Nuance.
  • With FDA clearance, our first product GIQuant can be used in combination with routine MRI to easily evaluate gastrointestinal function.
  • Peter Ellis, Chairman of Motilent says: "FDA clearance is an important step for Motilent as we move to the US market.

JTOWER and DOCOMO Decide to Form a Capital and Business Alliance

Monday, November 22, 2021 - 9:13am

TOKYO, Nov 22, 2021 - (JCN Newswire) - JTOWER Inc. ("JTOWER") and NTT DOCOMO, INC. ("DOCOMO") jointly announced today that they have decided to form a capital and business alliance ("the Capital and Business Alliance") with the aim of strengthening collaboration in the use of Infra-Sharing.

Key Points: 
  • TOKYO, Nov 22, 2021 - (JCN Newswire) - JTOWER Inc. ("JTOWER") and NTT DOCOMO, INC. ("DOCOMO") jointly announced today that they have decided to form a capital and business alliance ("the Capital and Business Alliance") with the aim of strengthening collaboration in the use of Infra-Sharing.
  • DOCOMO plans to acquire part of JTOWER shares held by NIPPON TELEGRAPH AND TELEPHONE CORPORATION and become a shareholder with 2.5% voting rights in the future.
  • DOCOMO started using the JTOWER's Infra-Sharing solution (IBS(1)) for its 4G network in 2016 and has expanded the use of the solution nationwide.
  • JTOWER and DOCOMO will use this alliance as an opportunity to strengthen collaboration.

Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

Friday, November 19, 2021 - 1:19pm

Colorectal cancer (CRC) is the second most common cause of cancer death in the United States.

Key Points: 
  • Colorectal cancer (CRC) is the second most common cause of cancer death in the United States.
  • Biomericas EZ Detect colorectal screening product is the simplest at home test to detect occult (hidden) blood in patient stools, an early warning sign of colorectal cancer.
  • Zackary Irani, Chairman and Chief Executive Officer, stated, We are excited to have Dr. Cash chair our Colorectal Screening Scientific Advisory Board to assist Biomerica with guiding our FDA cleared diagnostic test to help patients suffering from gastroenterology problems including colorectal cancer.
  • This is evidenced by the initial success of our InFoods IBS diagnostic guided therapy, in which our scientific advisory board played a vital role.

Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Thursday, November 11, 2021 - 12:05pm

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.
  • Research and development expenses were $3.0 million for the third quarter ended September 30, 2021, compared to $0.1 million for the third quarter ended September 30, 2020.
  • General and administrative expenses were $1.1 million for the third quarter ended September 30, 2021, as compared to $2.5 million for the third quarter ended September 30, 2020.
  • Virios Therapeutics management will host a webcast and conference call on November 11, 2021 at 8:30 a.m. EST to discuss the results and provide a corporate update.

4D pharma to Participate in Jefferies London Healthcare Conference

Thursday, November 11, 2021 - 12:00pm

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will participate in the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

Key Points: 
  • 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will participate in the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.
  • 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
  • 4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut.
  • The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

DGAP-News: Lindis Blood Care Announces Publication of Clinical Pilot Study Results Successfully Highlighting the Potential of CATUVAB(R) in the Removal of Tumor Cells from Surgical Blood in Peer-Reviewed Journal

Wednesday, November 10, 2021 - 9:02am

The publication "Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device - a pilot study" can be accessed online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555247/ .

Key Points: 
  • The publication "Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device - a pilot study" can be accessed online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555247/ .
  • CATUVAB(R) consists of a trifunctional antibody, that aggregates the tumor cells and lymphocytes, and a leukocyte depletion filter (LDF).
  • Results of the study showed, that after the CATUVAB(R) procedure, no malignant cells were detected in the final erythrocyte concentrates.
  • The product and process can be integrated easily into everyday clinical practice and become part of contemporary "patient blood management".

Prairie Grass Launches Cannabis Suppository for Medical Patients and Adult-Use Markets Across Canada

Tuesday, November 9, 2021 - 2:30pm

Grassy Lake, Alberta--(Newsfile Corp. - November 9, 2021) - Prairie Grass Inc. - A Canadian Licensed Producer is the first to bring a cannabis suppository to market, now available to medical patients across the country through Shelter Market .

Key Points: 
  • Grassy Lake, Alberta--(Newsfile Corp. - November 9, 2021) - Prairie Grass Inc. - A Canadian Licensed Producer is the first to bring a cannabis suppository to market, now available to medical patients across the country through Shelter Market .
  • Prairie Grass is launching two distinct formulations, both using input material extracted from their own farm grown cannabis.
  • For detailed medical information, Prairie Grass Inc. encourages you to seek professional medical advice through your family doctor.
  • Prairie Grass Inc. is a Canadian Cannabis Standard Cultivation and Processing license holder based in Grassy Lake, Alberta.